AIM movers: Premium fundraising for Ondine Biomedical and Roadside Real Estate gets more from stake sale

Ondine Biomedical (LON: OBI) is raising at least £3m at 7p/share to help fund the preparations for the US phase 3 clinical trial, as well as supporting sales of Steriwave nasal decolonisation. Steriwave more than halves post-surgical hospital infection rates. Further funding will be required for the clinical trial and FDA submission. The share price recovered 26.8% to 6.5p, but it is still well below the placing price.

Trading in Roadside Real Estate (LON: ROAD) shares recommenced following the release of its results for the 15 months to September 2023 and there was an increase of 15.9% to 9.5p. This has been a period of restructuring for the business and there is progress being made on the focus on roadside property. The reported loss was £10.2m. Subsidiary Cambridge Sleep Sciences has acquired the remaining SleepEngine-related IP rights. The partial sale of a stake in CSS has been completed, but the deal was amended so that it was worth £7.5m, which is more than before. Roadside Real Estate retains a 61.4% stake.

- Advertisement -

Angle (LON: AGL) has secured a deal with AstraZeneca to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies. This will generate income of £550,000. The share price moved up 12.7% to 15.5p.

Shares in UK Oil & Gas (LON: UKOG) have risen 6.25% to 0.0255p even though 10% of the enlarged share capital has been issued to the employee benefit trust at 0.0001p each.

Tekmar Group (LON: TGP) has sold loss making engineering consultancy Subsea Innovation for £1.9m with £549,000 of this payable in 12 months. Tekmar is retaining the Subsea Innovation premises, which are valued at £2.8m. The cash will be reinvested in the core subsea technology operations. The share price has improved 5.41% to 9.75p.


- Advertisement -

In-technology advertising technology provider Mirriad Advertising (LON: MIRI) has raised £6.12m at 1.25p/share. The share price slumped 39.1% to 1.325p. The cash will be spent on operating costs and technology development. In addition, a REX retail offer has been launched and that closes on 7 May.

Delays in contracts mean that pharma data company Physiomics (LON: PYC) will report lower than expected revenues for the year to June 2024. The indicated range is £600,000-£650,000. There are two contracts worth £350,000 in total are being negotiated and this is likely to be recognised next year. The share price fell 13.3% to 1.3p.

Currency services provider Argentex Group (LON: AGFX) has launched a retail offer at 45p/share, following yesterday’s placing. The share price has slipped a further 5.29% to 34p. The new chief executive wants to fund the transformation of the business.

Latest News

Subscribe to the UK Investor Magazine email newsletter

Register for our free email newsletter and receive the latest investment news, podcasts, event information and offers.

More Articles Like This

Tagdiv Cloud library - template content.